Unlocking the potential of the UK’s best, fast-growing businesses.

When it comes to science and technology scale-up investment, Britain has reached a crossroads.

Great potential rests in the UK’s high growth businesses – both those that already exist, and those bound to emerge from our best-in-class research and development ecosystem. At present, though, much of this potential lies dormant.

If the private sector moves quickly – with the support of the government, politicians, and the public sector – we can unlock the capital needed to nurture, retain, and develop our most promising startups and spinouts.

Not only will these companies thrive as a result, but Britain’s economy will reap the rewards.

Failing this, the consequences are stark. We risk losing our best businesses to overseas markets. It’s likely we also surrender the chance of significant and imminent economic growth.

And we almost certainly resign ourselves to the role of follower in the fast-accelerating scientific and technological revolution, rather than leader.

It’s a positive sign, then, that there is consensus across much of the financial services industry on the need to improve the funding environment for these high growth companies. So, too, is it encouraging that unlocking pension fund capital is considered key.

Most importantly, though, there is acknowledgement of the need to act now, to make Britain the best and most accessible location for major investment – both domestic and overseas.

At Future Planet Capital, we’re able to say this with confidence, having consulted with leading entrepreneurs, major investors and asset managers in the UK and beyond, and key figures in the insurance and pensions industry.

As a result, we’re able to set out a clear five-step plan of action for realising these shared goals:

  1. Managers of insurance and pension assets should work closely with the wider investment industry, to ensure they have the necessary skills, expertise, and partnerships to direct capital towards the UK’s high growth businesses.

  2. Insurers and pension funds should look to move quicker than set out in last year’s Mansion House reforms, aiming to outperform the current goal of nine funds allocating 5% of capital into unlisted and early-stage companies by 2030.

  3. Investors should look to deploy capital in every region of the UK, with LEPs and local and combined authorities offering investors a single point of contact for investing in their areas.

  4. Ministers should make investing in the UK more straightforward by implementing in full the recommendations of the recent Foreign Direct Investment Review by the end of the current year.

  5. Politicians should set clear and consistent priority sectors for investment and provide long-term support for these sectors including public sector co-investment.

If Britain is to support its high growth scaleups – and see the results from doing so – we must take these steps. Our industry-wide conversations have provided confidence in the appetite to do so. It’s time to act on these discussions and get much-needed capital moving in the right direction.

Engineering Biology: High Impact, High Growth

*|MC:SUBJECT|*

Engineering Biology:

High Impact, High Growth

“Engineering biology is a powerful underlying technology that enables new products and manufacturing approaches in numerous vertical sectors. It drives a more sustainable approach to manufacturing, offering high impact replacement products as well as those with truly novel functionality. It is as transformative as AI’ explains Oliver Sexton, Investment Director from the UKI2S Fund. “We back companies using engineering biology as a core part of our investment thesis as it strongly selects high impact, high growth entities competing with robust IP in very large markets with ground breaking solutions.”


FPC is a global impact-led venture capital firm headquartered in London. It manages the £102M UK Innovation and Science Seed Fund (UKI2S) which has £33m of capital dedicated to engineering biology investments. FPC is focused on investing in these and other high-growth businesses that contribute positively to societal and environmental issues as well as aligning with the UN Sustainable Development Goals.


With a portfolio of 140 companies notable exits include 23andMe, a genetic testing company, and OxfordVR, specialising in virtual reality therapy for mental health and Quethera, an eng bio biotech.


UKI2S is an early-stage investment fund that nurtures innovative businesses from great UK science to leverage private investment and grow jobs. The fund is backed by the Department for Science, Innovation and Technology and other public bodies, including UKRI UKAEA and MOD. This fund has supported a wide array of companies in sectors ranging from therapeutics and agritech to clean biotech.


Technology development using engineering biology is potentially high return. Whilst biology is complex, by applying engineering principles and breaking down pathways to key steps, it can be de-risked and also enhanced. Whilst this complexity means investors may face some worrying moments as technology develops it means the end solution is novel, highly functional and very differentiated. An engineering biology company isn’t going after incremental improvements, it will replace a product with a superior solution.  


FPC has a dedicated team to aid in the evaluation of technical innovation. “In the UK team, there are individuals with PhD and masters qualifications in STEM subjects to carry out due diligence. We also utilise external consultants to help understand the science behind a company’s product. We couple this with discussions with potential customers to understand a product’s viability,” says Sexton.


Delivering such complex R&D efficiently and quickly means learning from others. Accelerator programmes can provide companies with useful exposure to investors and opportunities to secure investment and as importantly, training in planning, budgeting and managing companies. FPC has co invested alongside accelerator programmes and Sexton explains, “There are some programmes with very good reputations and have produced great things. We may invest in parallel whilst a business is participating in an accelerator programme. Often, the amount of equity provided by the accelerator is not sufficient, especially in biology,” says Sexton.


Sexton explains how businesses benefit from FPC investment, “We have a rich network and dedicate time to helping teams focus the plans and business model. We really try hard to introduce companies to other funds, to executives and board members. It is also not uncommon for us to provide connections and then invest in a business at a later stage as plans develop. FPC is also well connected to corporates. This allows us to help portfolio companies find corporate customers or corporate investment.”


Sexton highlights the importance of compatibility between entrepreneurs and investors: “Investing is more than equity. You need your investor to be supportive and helpful throughout. As you will be working together over time its fundamental to make a good team.”


EngBio has a huge potency and potential to be beneficial to society: The BBSRC shares how UKI2S is doing this

The Biotechnology and Biological Sciences Research Council (BBSRC) has invested £33m in UKI2S’ EngBio fund, acting as a pathway in research and commercialisation in the EngBio sector.


EngBio has a huge potency and potential to be beneficial to society; driving economic growth and importantly, protecting the planet.


Click on the video above to hear Nick Bassett, Associate Director of Innovation for BBSRC sharing what makes UKI2S special

How Start-Ups Can Boost Online Visibility with Venture Capitalists


Peter Mitchell, our very own Head of Origination - and a data scientist, whose job it is to find start-ups online - this month gives his advice on how start-ups can boost their online presence.


Peter says: The venture capital industry is increasingly data-driven, and it’s essential for CEOs to adapt to this trend to enhance your visibility and appeal. Here are some practical tips to increase your online presence with venture capitalists, from a data scientist whose job it is to find start-ups online!


Learn more by reading Peter’s piece here.


Improve efficiency, productivity and sustainability with Productive Machines


NetZero by 2030. Responsible investment. Environmental action. Social inclusion. Impact-first – that’s the mission. The driving force behind UKI2S, managed by Future Planet Capital.


In line with COP28, it’s time to show you how we’re working with innovative startups to facilitate the change we all want, and need, to see.


Productive Machines is on a mission to revolutionise the productivity of machine tools. It uses digital twin technology to simulate millions of different machine settings in order to find the most optimal combinations that minimise waste and energy consumption.


Chatter, a longstanding issue in machining, has plagued manufacturers for decades.

It disrupts operations, resulting in slower cycle times, increased waste, surface irregularities, and dimensional inaccuracies.


In order to minimise vibrations, human trial and error has long been the only solution.


Until now. Productive Machines’ advanced technology can eliminate chatter in machining, leading to key sustainability benefits including waste reduction, resource efficiency, energy conservation, enhanced product quality, equipment lifespan, and safer workplaces.


Read more about FPC, UKI2S and Productive Machines.

Find out more about Future Planet Capital by visiting our website.

Dinner is Served

*|MC:SUBJECT|*

Dinner is Served

As we step into 2024 we wanted to reflect on what’s been going on here at FPC and, in this edition, particularly in the context of our early stage innovation-focussed fund UK Innovation & Science Seed Fund (UKI2S).


We’ve spent a lot of time discussing, exploring and working out how best to support the multitude of innovative ideas that our great founders of today are eager to bring to market. Because that’s my biggest finding thus far; your innovations are only as good as your ability to commercialise them.


So what happened in 2023?


At the end of 2022, cash inflow within the venture capital industry had dropped by 90%. Inflation was rapidly rising and interest rates were going up with it.


There was a profound sense of pessimism within the industry and so 2023 was spent working on existing portfolio companies – just trying to keep them alive.


Organisations needed to generate enough revenue to cover costs and break even with bridge rounds. Incredibly, many companies achieved that. I think it’s fair to say that the bleak clarity everyone had coming into 2023 set them up to over-achieve; the forecast under-promised, many ended up over-delivering.


It was a good year here at FPC – we grew our assets by 20% – mainly driven by investment from the government in their determination to commercialise and scale up… As for 2024… we will be very busy again but one issue will be top of mind.


Climate change is no longer an existential threat for the decades ahead – it’s evidenced in the geopolitical realities we face today.


As we witnessed during COP28, Abu Dhabi and the UAE were willing to lead the charge to voluntarily act to reduce fossil fuel usage.  Their role and diplomatic skill in including fossil fuels for the very first time at a COP meeting was notable.  And yet it really shouldn’t have been.  The negative impact of continued fossil-fuel-driven climate change is undeniable – countries across the globe are facing water shortages, high levels of air pollution, financial poverty, loss of biodiversity and insufficient food security.


As a result, we’re facing crises of both environmental and human health. And it won’t stop there unless we focus on making drastic changes in one particular industry currently dependent on hydrocarbons: food.  


We must create sustainable food systems and work towards ensuring global food security. Over 2024 we’ll be looking to focus on food and related life sciences as one of our top priorities.


How can we do that?  Click here to read the rest of Douglas' piece and learn more.  


EngBioX

EngBioX Highlight Film

Thank you to everyone who attended EngBioX


We learnt so much about the industry from the fantastic speakers - CellCentric, twig, Pencil Biosciences Limited, and Antiverse.


The atmosphere was amazing. Watch the video above to learn more.

Norman Foster named Domus Guest Editor for 2024


Future Planet Capital Advisory Board Chairman, Lord Norman Foster, has been announced as the Guest Editor of architectural magazine Domus.  


Last month, Lord Foster was interviewed for Domus, which resulted in a fascinating article which is highly recommended reading. This month, Lord Foster has released his first editorial which outlines his plans for Domus and opens his exploration of the theme “Futures”.


“The state of our cities, the state of our architecture, is the state of our civilisation. The art of building is about the human spirit, about spiritual as well as material needs.”


“To embrace the future in the master plan of a city or in the design of a building is an act of forward-thinking optimism.”


Read a copy of the editorial here.


We can’t wait to read the future editions!


Find out more about Future Planet Capital by visiting our website.